Digitalni repozitorij raziskovalnih organizacij Slovenije

Izpis gradiva
A+ | A- | SLO | ENG

Naslov:Dexamethasone in hospitalized patients with Covid-19
Avtorji:ID Horby, Peter (Avtor)
ID Lim, Wei Shen (Avtor)
ID Kačar, Mark (Z enoto povezano ime)
ID Landray, Martin J. (Avtor)
ID Kačar, Mark (Sodelavec pri raziskavi)
Datoteke:URL URL - Priloga, za dostop obiščite https://www.nejm.org/doi/10.1056/NEJMoa2022926?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%20%200pubmed#article_supplementary_material
 
URL URL - Izvorni URL, za dostop obiščite https://www.nejm.org/doi/pdf/10.1056/NEJMoa2021436?articleTools=true
 
Jezik:Angleški jezik
Tipologija:1.01 - Izvirni znanstveni članek
Organizacija:Logo UKPBAG - Univerzitetna klinika za pljučne bolezni in alergijo Golnik
Povzetek:Background: Coronavirus disease 2019 (Covid-19) is associated with diffuse lung damage. Glucocorticoids may modulate inflammation-mediated lung injury and thereby reduce progression to respiratory failure and death. Methods: In this controlled, open-label trial comparing a range of possible treatments in patients who were hospitalized with Covid-19, we randomly assigned patients to receive oral or intravenous dexamethasone (at a dose of 6 mg once daily) for up to 10 days or to receive usual care alone. The primary outcome was 28-day mortality. Here, we report the final results of this assessment. Results: A total of 2104 patients were assigned to receive dexamethasone and 4321 to receive usual care. Overall, 482 patients (22.9%) in the dexamethasone group and 1110 patients (25.7%) in the usual care group died within 28 days after randomization (age-adjusted rate ratio, 0.83; 95% confidence interval [CI], 0.75 to 0.93; P<0.001). The proportional and absolute between-group differences in mortality varied considerably according to the level of respiratory support that the patients were receiving at the time of randomization. In the dexamethasone group, the incidence of death was lower than that in the usual care group among patients receiving invasive mechanical ventilation (29.3% vs. 41.4%; rate ratio, 0.64; 95% CI, 0.51 to 0.81) and among those receiving oxygen without invasive mechanical ventilation (23.3% vs. 26.2%; rate ratio, 0.82; 95% CI, 0.72 to 0.94) but not among those who were receiving no respiratory support at randomization (17.8% vs. 14.0%; rate ratio, 1.19; 95% CI, 0.92 to 1.55). Conclusions: In patients hospitalized with Covid-19, the use of dexamethasone resulted in lower 28-day mortality among those who were receiving either invasive mechanical ventilation or oxygen alone at randomization but not among those receiving no respiratory support. (Funded by the Medical Research Council and National Institute for Health Research and others; RECOVERY ClinicalTrials.gov number, NCT04381936; ISRCTN number, 50189673.).
Ključne besede:Covid-19 -- drug therapy, dexamethasone
Leto izida:2021
Status objave pri reviji:Objavljeno
Verzija članka:Založnikova različica članka
Založnik: Massachusetts Medical Society
Št. strani:str. 693-704
Številčenje:Vol. 384, iss. 8
Izvor:ZDA
PID:20.500.12556/DiRROS-15123 Novo okno
UDK:616.9
ISSN pri članku:1533-4406
DOI:10.1056/NEJMoa2021436 Novo okno
COBISS.SI-ID:109711875 Novo okno
Avtorske pravice:© 2021, Massachusetts Medical Society
Opomba:Nasl. z nasl. zaslona; Član raziskovalne skupine iz Slovenije: Mark Kačar; Opis vira z dne 30. 5. 2022;
Datum objave v DiRROS:30.05.2022
Število ogledov:190
Število prenosov:138
Metapodatki:XML RDF-CHPDL DC-XML DC-RDF
:
Kopiraj citat
  
Objavi na:AddThis
AddThis uporablja piškotke, za katere potrebujemo vaše privoljenje.
Uredi privoljenje...

Postavite miškin kazalec na naslov za izpis povzetka. Klik na naslov izpiše podrobnosti ali sproži prenos.

Gradivo je del revije

Naslov:The New England journal of medicine
Skrajšan naslov:New Engl. j. med.
Založnik:Massachusetts Medical Society, NEJM Group
ISSN:1533-4406
COBISS.SI-ID:520038169 Novo okno

Licence

Licenca:CC BY 4.0, Creative Commons Priznanje avtorstva 4.0 Mednarodna
Povezava:http://creativecommons.org/licenses/by/4.0/deed.sl
Opis:To je standardna licenca Creative Commons, ki daje uporabnikom največ možnosti za nadaljnjo uporabo dela, pri čemer morajo navesti avtorja.
Začetek licenciranja:25.02.2021

Sekundarni jezik

Jezik:Ni določen
Ključne besede:covid-19 -- terapija z zdravili, deksametazon


Nazaj